Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Clinical trials

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. Results Donanemab reduced the risk of progression from MCI to mild AD by 33% (hazard ratio [HR] = 0.67; 95% CI 0.52-0.87; p = 0.003) and from mild to moderate AD by 50% (HR = 0.50; 95% CI 0.33-0.78; p = 0.002). Discussion These results add to the evidence and further support clinically meaningful donanemab-mediated effects on cognition and function for patients and their caregivers and may aid communication of realistic treatment expectations and informed decision-making. Start date of recruitment: June 19, 2020. clinicaltrialsregister.eu/ctr-search/trial/2020-000077-25/results.

What this study adds

Evidence grade: Moderate

In this Phase 3 trial, donanemab reduced the risk of progression from mild cognitive impairment to mild Alzheimer's disease by 33% and from mild to moderate Alzheimer's disease by 50%. Its stated limit: Authored by manufacturer employees and consultants; several analyses are post hoc; relative risk reductions can sound larger than the underlying absolute differences; 76-week horizon; the trial excluded many typical patients.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Atri, A., Apostolova, L. G., Iwata, A., Wessels, A. M., Atkins, A., Lu, M., et al. (2026). Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. Neurology: Clinical Practice. https://doi.org/10.1212/CPJ.0000000000200621

Vancouver

Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, et al. Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. Neurology: Clinical Practice. 2026. doi:10.1212/CPJ.0000000000200621. PMID: 42128444.

BibTeX

@article{atri2026-42128444,
  author  = {Atri, A. and Apostolova, L. G. and Iwata, A. and Wessels, A. M. and Atkins, A. and Lu, M. and Ye, W. and Ryan, S. and Doty, E. G.},
  title   = {{Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial}},
  journal = {Neurology: Clinical Practice},
  year    = {2026},
  doi     = {10.1212/CPJ.0000000000200621},
  pmid    = {42128444},
  url     = {https://doi.org/10.1212/CPJ.0000000000200621}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In this Phase 3 trial, donanemab reduced the risk of progression from mild cognitive impairment to mild Alzheimer's disease by 33% and from mild to moderate Alzheimer's disease by 50%. These results support clinically meaningful effects on cognition and function for patients with early symptomatic Alzheimer's disease.

Study details

Limitations

Authored by manufacturer employees and consultants; several analyses are post hoc; relative risk reductions can sound larger than the underlying absolute differences; 76-week horizon; the trial excluded many typical patients.

How this study scored 63/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 5 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 59 of the 94 points it could be judged on, which is 63 of 100. Total 63 of 100.59 of the 94 points we could judge = 63 of 100

Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for sample size and studied in people because the record does not state it. We have no data on journal's citation record and free to read, so those were left out: it earned 59 of the 94 points we could judge it on, which is 63 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurology: Clinical Practice)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A large phase 3 trial
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 2 / 7 Cited 6 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.0 citations a year over 2 year(s) since 2026
Impact for its field and year 5 / 6 Cited 24.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Erin Gautier Doty: h-index 15 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42128444)
Free to read — / 2 Access not recorded — left out of this score
Points 59 / 94 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 59 of the 94 points we could judge it on is 63 out of 100.
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Clinical trials from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →